Private Advisor Group LLC trimmed its position in Addus HomeCare Co. (NASDAQ:ADUS – Free Report) by 6.0% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,698 shares of the company’s stock after selling 172 shares during the period. Private Advisor Group LLC’s holdings in Addus HomeCare were worth $359,000 as of its most recent SEC filing.
A number of other institutional investors have also recently added to or reduced their stakes in the company. Allspring Global Investments Holdings LLC lifted its position in Addus HomeCare by 48.4% in the third quarter. Allspring Global Investments Holdings LLC now owns 70,231 shares of the company’s stock worth $9,343,000 after purchasing an additional 22,900 shares during the period. Net Worth Advisory Group acquired a new stake in Addus HomeCare in the third quarter worth approximately $356,000. Ellsworth Advisors LLC lifted its position in Addus HomeCare by 3.7% in the third quarter. Ellsworth Advisors LLC now owns 5,344 shares of the company’s stock worth $711,000 after purchasing an additional 193 shares during the period. Creative Planning lifted its position in Addus HomeCare by 5.8% in the third quarter. Creative Planning now owns 4,910 shares of the company’s stock worth $653,000 after purchasing an additional 267 shares during the period. Finally, Oliver Luxxe Assets LLC lifted its position in Addus HomeCare by 244.8% in the third quarter. Oliver Luxxe Assets LLC now owns 16,512 shares of the company’s stock worth $2,197,000 after purchasing an additional 11,723 shares during the period. 95.35% of the stock is currently owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
A number of research firms have weighed in on ADUS. Royal Bank of Canada restated an “outperform” rating and issued a $141.00 target price on shares of Addus HomeCare in a research report on Tuesday, September 3rd. Macquarie reaffirmed an “outperform” rating and issued a $139.00 price target on shares of Addus HomeCare in a report on Monday. Oppenheimer upped their price target on Addus HomeCare from $140.00 to $145.00 and gave the company an “outperform” rating in a report on Monday, September 23rd. TD Cowen upped their price target on Addus HomeCare from $128.00 to $137.00 and gave the company a “buy” rating in a report on Thursday, August 8th. Finally, Stephens reaffirmed an “overweight” rating and issued a $138.00 price target on shares of Addus HomeCare in a report on Tuesday, August 6th. One investment analyst has rated the stock with a sell rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $131.38.
Addus HomeCare Trading Down 3.7 %
NASDAQ ADUS opened at $124.17 on Wednesday. Addus HomeCare Co. has a 1-year low of $81.51 and a 1-year high of $136.12. The company has a market capitalization of $2.25 billion, a PE ratio of 28.13, a price-to-earnings-growth ratio of 2.29 and a beta of 1.04. The firm’s fifty day simple moving average is $129.93 and its 200-day simple moving average is $120.66.
Addus HomeCare (NASDAQ:ADUS – Get Free Report) last issued its quarterly earnings data on Monday, November 4th. The company reported $1.30 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.28 by $0.02. The firm had revenue of $289.80 million during the quarter, compared to analysts’ expectations of $289.42 million. Addus HomeCare had a net margin of 6.18% and a return on equity of 9.81%. Addus HomeCare’s revenue for the quarter was up 7.1% on a year-over-year basis. During the same period in the prior year, the company posted $1.03 earnings per share. As a group, analysts predict that Addus HomeCare Co. will post 4.57 EPS for the current year.
Insider Buying and Selling
In other Addus HomeCare news, Director Esteban Lopez sold 500 shares of the company’s stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $130.03, for a total transaction of $65,015.00. Following the completion of the sale, the director now directly owns 3,866 shares in the company, valued at $502,695.98. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Addus HomeCare news, Director Esteban Lopez sold 500 shares of the company’s stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $130.03, for a total transaction of $65,015.00. Following the completion of the sale, the director now directly owns 3,866 shares in the company, valued at $502,695.98. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Michael D. Wattenbarger sold 21,917 shares of the company’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $133.29, for a total transaction of $2,921,316.93. Following the sale, the executive vice president now owns 7,215 shares of the company’s stock, valued at $961,687.35. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 22,917 shares of company stock worth $3,050,082. Corporate insiders own 4.60% of the company’s stock.
Addus HomeCare Company Profile
Addus HomeCare Corporation, together with its subsidiaries, provides personal care services to elderly, chronically ill, disabled persons, and individuals who are at risk of hospitalization or institutionalization in the United States. The company operates through three segments: Personal Care, Hospice, and Home Health.
Featured Stories
- Five stocks we like better than Addus HomeCare
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Palantir Cracks $50, Is There Still Time to Get on Board?
- Why Are These Companies Considered Blue Chips?
- Insider Buying Signals Upside for These 3 Stocks
- Investing In Preferred Stock vs. Common Stock
- These 2 Big Players Are Set to Compete With Elon Musk’s Starlink
Receive News & Ratings for Addus HomeCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Addus HomeCare and related companies with MarketBeat.com's FREE daily email newsletter.